Current Attempt in Progress

Amy Dylan, controller at Marizold Pharmaceutical Industriss, a public company, is currantly praparing the caleulation for basic and

diluted earnings per share and the ralated disclosure for Mariyold's financial statamants. Below is selected financial information for

the fiscal year anded June $30,2025.$

Shareholders' equity

The following transactions have also occurred at Marigold.

Options ware granted on July $1,2024,$ to purchase $190,000$ shares at $$16$ per share. A$/$though no options ware exarciesd

during fiscal year $2025,$ the average price per common share during fiscal year $2025$ was $$20$ per share.

Each bond was issued at face value. The $9\%$ convertible bonds will convert into common stock at $50$ shares per $$1,000$ bond.

The bonds are exarcisable after $5$ years and were issued in fiscal yaar $2024.$

The preferred stock was issued in $2024.$

There are no preferred dividends in arrars; however, preferred dividends wers not declarad in facal year $2025.$

The $990,000$ shars of common stock wers outstanding for the entire $2025$ fiscal year.

Net income for fiscal year $2025$ was $$1,520,000,$ and the avarage income tax rate is $20\%.$

For the fiscal year ended June $30,2025,$ calculate the following for Marigold Pharmaceutical Industries. $($Round answers to $2$ decimal

places, eg$.2\mathrm{.}45.)$

Basic earnines per share

Basicearnings pershare $

b$.$ Dilutad earnings per share

Dilutad earnings per share $

eTextbook and Media